Studies confirm the involvement of Sig1R in the seizure modulation

Researchers at the Laboratory of Pharmaceutical Pharmacology (LIOS) in their latest publication have demonstrated that sigma-1 receptor (Sig1R) is a valuable target for the development of novel anti-seizure drugs. Research has been published in the journal “Neurobiology of Disease” (IF = 5.332, 2019).

Vavers, E.; Zvejniece, B.; Stelfa, G.; Svalbe, B.; Vilks, K,; Kupats, E.; Mezapuke, R.; Lauberte, L.; Dambrova, M.; Zvejniece, L.
Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures.
Neurobiol. Dis. 2021, 150, 105244. DOI: 10.1016/j.nbd.2020.105244

Unlabelled Image

This study was supported by the European Regional Development Fund Project No. (PostDoc Latvia), “Sigma chaperone protein as a novel drug target”.